Therapeutic Targeting of TP53-mutated Acute Myeloid Leukemia by Inhibiting HIF-1α with Echinomycin

[1]  Beth Wilmot,et al.  Functional Genomic Landscape of Acute Myeloid Leukemia , 2018, Nature.

[2]  Shaoguang Li,et al.  Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine. , 2017, Blood.

[3]  Christopher A. Miller,et al.  TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. , 2016, The New England journal of medicine.

[4]  A. Shelling,et al.  Nanoparticle therapeutics: Technologies and methods for overcoming cancer. , 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[5]  B. Ko,et al.  TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution , 2015, Blood Cancer Journal.

[6]  H. Kantarjian,et al.  TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases , 2015, Journal of Hematology & Oncology.

[7]  D. Neuberg,et al.  Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Caligiuri,et al.  Echinomycin protects mice against relapsed acute myeloid leukemia without adverse effect on hematopoietic stem cells. , 2014, Blood.

[9]  C. Preudhomme,et al.  Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine. , 2014, Leukemia research.

[10]  O. Abdel-Wahab,et al.  Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia , 2013, Haematologica.

[11]  J. Silverman,et al.  Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine , 2012, Cancer Chemotherapy and Pharmacology.

[12]  H. Xi,et al.  HIF1α is required for survival maintenance of chronic myeloid leukemia stem cells. , 2011, Blood.

[13]  Yang Liu,et al.  Targeting HIF1α eliminates cancer stem cells in hematological malignancies. , 2011, Cell stem cell.

[14]  Kerby Shedden,et al.  Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia. , 2010, Blood.

[15]  W. Tong,et al.  Pivotal role for glycogen synthase kinase-3 in hematopoietic stem cell homeostasis in mice. , 2009, The Journal of clinical investigation.

[16]  T. Haferlach,et al.  Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype , 2008, Leukemia.

[17]  G. Wahl,et al.  Regulating the p53 pathway: in vitro hypotheses, in vivo veritas , 2006, Nature Reviews Cancer.

[18]  H. Maeda,et al.  Exploiting the enhanced permeability and retention effect for tumor targeting. , 2006, Drug discovery today.

[19]  A. Monks,et al.  Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. , 2005, Cancer research.

[20]  M. Schindl,et al.  Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[22]  T. Fojo,et al.  p53 Inhibits Hypoxia-inducible Factor-stimulated Transcription* , 1998, The Journal of Biological Chemistry.

[23]  B. Groner,et al.  Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain , 1997, Nature Medicine.

[24]  S. Ben-Neriah,et al.  Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. , 1996, Blood.

[25]  B. Quesnel,et al.  p53 Mutations Are Associated With Resistance to Chemotherapy and Short Survival in Hematologic Malignancies , 1994 .

[26]  Koichi Sugimoto,et al.  Frequent mutations in the p53 gene in human myeloid leukemia cell lines. , 1992, Blood.

[27]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[28]  M. Isobe,et al.  Localization of gene for human p53 tumour antigen to band 17p13 , 1986, Nature.

[29]  S. Fröhling,et al.  TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. , 2012, Blood.

[30]  Pramod Kumar,et al.  Liposomes a vesicular nanocarrier: potential advancements in cancer chemotherapy. , 2012, Critical reviews in therapeutic drug carrier systems.

[31]  Magali Olivier,et al.  TP53 mutations in human cancers: origins, consequences, and clinical use. , 2010, Cold Spring Harbor perspectives in biology.

[32]  H. Zähner,et al.  Stoffwechselprodukte von Actinomyceten. 7. Mitteilung. Echinomycin , 1957 .